#STXS
🚨 $STXS
Benfer David () bought 30,000 shares at an average price of $0.8290 per common share. (Date: 2026-11-17)
SEC Filing: STXS
Click to view the official SEC document.
www.sec.gov
November 19, 2026 at 2:45 AM
🚨 $STXS
Menawat Arun Swarup () bought 121,561 shares at an average price of $0.8225 per common share. (Date: 2026-11-17)
SEC Filing: STXS
Click to view the official SEC document.
www.sec.gov
November 19, 2026 at 2:45 AM
🚨 $STXS
Isaac Paul J (Insider) bought 13,300 shares at an average price of $0.8195 per common share. (Date: 2026-11-17)
SEC Filing: STXS
Click to view the official SEC document.
www.sec.gov
November 18, 2026 at 8:37 PM
Stereotaxis ($STXS) – Insider Purchase

• Insider: David Benfer, Director
• Bought: 30,000 shares (about $25K)
• Price: about $0.83 a share · Nov 17
• Cluster: 3 insiders bought in the last 30 days

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#InsiderBuying #Stocks
David Benfer (Director) bought $25K of Stereotaxis ($STXS)
Form 4 filed Nov 18. Every line of the filing.
elixstocks.com
November 19, 2026 at 12:04 PM
Stereotaxis ($STXS) – Insider Purchase

• Insider: Arun Swarup Menawat, Director
• Bought: 121,561 shares (about $100K)
• Price: about $0.82 a share · Nov 17
• Filed: Nov 18 · Form 4

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#InsiderBuying #Stocks
Arun Swarup Menawat (Director) bought $100K of Stereotaxis ($STXS)
Form 4 filed Nov 18. Every line of the filing.
elixstocks.com
November 19, 2026 at 11:51 AM
Stereotaxis ($STXS) – Insider Purchase

• Insider: Paul J Isaac, Director
• Bought: 13,300 shares (about $11K)
• Price: about $0.82 a share · Nov 16-17
• Cluster: 3 insiders bought in the last 30 days

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#InsiderBuying #Stocks
Paul J Isaac (Director) bought $11K of Stereotaxis ($STXS)
Form 4 filed Nov 18. Every line of the filing.
elixstocks.com
November 19, 2026 at 12:05 PM
3-month update: We called STXS a SELL. It's down 39.6% since -- we were right, so far.

lf0.com ↗
November 16, 2026 at 7:00 PM
🚨 $STXS
On November 10, 2026, the Company issued a press release setting forth its financial results for the 2026 third quarter.
SEC Filing: STXS
Click to view the official SEC document.
www.sec.gov
November 10, 2026 at 9:09 PM
$STXS lands $24M convertible note at 10% interest, aiding R&D and commercialization but risking shareholder dilution. $PEPG $XCUR $CLLS $ALGS $STIM $SNOA $GOSS $INO $MDAI

www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 11/11/26
export-download.canva.com
November 11, 2026 at 1:40 PM
#STXS First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT

https://www.stocktitan.net/news/STXS/first-in-human-coronary-intervention-study-results-of-robocath-s-re26yta0wugm.html?utm_source=stocktitan-bluesky&utm_medium=social
First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
Stereotaxis (STXS) announced first-in-human study results showing 100% clinical success for subsidiary Robocath’s next-generation robotic system in coronary interventions.The prospective pilot enrolled 20 patients undergoing percutaneous coronary intervention, a procedure to open narrowed coronary arteries. Technical success was 95%, with all but one procedure completed entirely robotically without conversion to manual. No device-related adverse events were reported through 30-day follow-up. The study included several levels of lesion complexity, and operating physicians had no fluoroscopy radiation exposure. Findings were presented at TCT on November 1, 2026; a manuscript is under review. Stereotaxis plans to progress the technology toward regulatory submissions.
www.stocktitan.net
November 2, 2026 at 1:49 PM
BUY_ON_CONFIRMATION $STXS (STXS.A) [StrategicCollaboration] New Collaboration; Announced @ 12:03:00Z
October 30, 2026 at 12:03 PM
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
Stereotaxis (NYSE: STXS) and Canon Medical Systems USA announced a technology compatibility and commercial collaboration pairing their robotic navigation and imaging systems. The companies are collaborating to offer Canon’s Alphenix interventional imaging platform alongside Stereotaxis’ GenesisX Robotic Magnetic Navigation system in a compatible configuration.Alphenix provides imaging and workflow capabilities for interventional cardiology. GenesisX navigates interventional catheters robotically and is designed for use in existing catheterization labs without construction. The companies aim to give hospitals more flexibility when planning robotic electrophysiology labs and will explore workflow improvements and additional capabilities. Their technologies will be presented at TCT 2026 in Canon’s booth.
www.stocktitan.net
October 30, 2026 at 12:03 PM
#$STXS update: we rated it SELL on Aug 17 with the stock at $1.39. It's now $0.97, down 30.2%. A $10,000 short from our entry would be up about $3,019. https://lf0.com/research/stereotaxis-stock-analysis-stxs/
October 29, 2026 at 1:45 PM
RRIDs were included in this in PLOS Biology paper. Thanks for making your methods matter! #RRID #OpenResearch #accelerateopenscience
Genome-wide CRISPR screens for Shiga toxins and ricin reveal Golgi proteins critical for glycosylation
Author summary Shiga and Shiga-like toxins (Stxs) are a family of bacterial toxins and key virulence factors for the bacteria Shigella dysenteriae and enterohemorrhagic Escherichia coli (EHEC), which cause food poisoning throughout the world. Ricin is a plant toxin and a potential bioterrorism agent. Stxs recognize the host receptor glycolipid Gb3, while ricin utilizes a broad range of glycans as receptors. Here, we carried out genome-wide loss-of-function CRISPR-Cas9 screens using human cells to identify factors required for Stxs and ricin. Besides host factors previously known to be involved in the action of these toxins, our screens revealed three previously poorly characterized Golgi proteins: LAPTM4A, which is specifically required for Stxs, and TMEM165 and TM9SF2, which are required for both Stxs and ricin. Further characterization demonstrates that LAPTM4A is specifically required for biosynthesis of the glycolipid Gb3, potentially acting as an “activator” protein fo
doi.org
October 30, 2026 at 7:05 AM
We called STXS a SELL. It's down 24.5% since -- we were right, so far.

lf0.com ↗
October 23, 2026 at 11:37 AM
We called STXS a SELL. It's down 5.0% since -- we were right, so far.

lf0.com ↗
September 16, 2026 at 9:00 PM
the man needs subscribers www.youtube.com/watch?v=stxs...
Celtic v Aberdeen Live Watch Along Show.
YouTube video by Ally Begg ABTV
www.youtube.com
September 2, 2026 at 8:19 PM
And I want you to know by listening to the album. You can use these codes om bandcamp to get the album for free.

Thank you.

lcmg-6edz
qpry-y7wg
gfln-7vl3
ywsv-j9ps
2jq7-k87d
d9bd-gnqh
stxs-um65
6kbc-6bdf
k3vc-yhxa
uagq-bvab
m9kf-wk3w
I am again encouraged, due to some very sad news from some friends, to let you know that love just simply doesn't disappear when the people you love go.

"Ambitions" is a song that I believe will help you. Though you may not be able to see it now.

Your love is real.
May 15, 2026 at 11:45 PM
Stereotaxis Wins FDA Clearance for Synchrony System: Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures. 👈 Read full analysis #Stereotaxis #FDAClearance #SynchronySystem #CatheterAblation #STXS
Stereotaxis Wins FDA Clearance for Synchrony System
Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures.
dlvr.it
April 6, 2026 at 12:56 PM